Global NASH Drug Pipeline Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “NASH Drug Pipeline Industry Forecast” looks at past sales and reviews total world NASH Drug Pipeline sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH Drug Pipeline sales for 2023 through 2029. With NASH Drug Pipeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NASH Drug Pipeline industry.
This Insight Report provides a comprehensive analysis of the global NASH Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH Drug Pipeline market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH Drug Pipeline.
The global NASH Drug Pipeline market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key NASH Drug Pipeline players cover Intercept, Genfit, Allergan, Madrigal, Immuron, Galectin, Gilead, 89bio Inc and ABIONYX Pharma SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of NASH Drug Pipeline market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global NASH Drug Pipeline market?
What factors are driving NASH Drug Pipeline market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NASH Drug Pipeline market opportunities vary by end market size?
How does NASH Drug Pipeline break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “NASH Drug Pipeline Industry Forecast” looks at past sales and reviews total world NASH Drug Pipeline sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH Drug Pipeline sales for 2023 through 2029. With NASH Drug Pipeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NASH Drug Pipeline industry.
This Insight Report provides a comprehensive analysis of the global NASH Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH Drug Pipeline market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH Drug Pipeline.
The global NASH Drug Pipeline market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for NASH Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key NASH Drug Pipeline players cover Intercept, Genfit, Allergan, Madrigal, Immuron, Galectin, Gilead, 89bio Inc and ABIONYX Pharma SA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of NASH Drug Pipeline market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- By Mechanism of Action
- Protease Inhibitor
- Immunomodulatory
- Multiple Kinase Inhibitor
- By Molecule Types
- Small molecule
- Stem Cell Therapy
- Gene Therapy
- By Route of Administration:
- Inhalation
- Intravenous
- Oral
- Subcutaneous
- Clinical
- Academic Research
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Intercept
- Genfit
- Allergan
- Madrigal
- Immuron
- Galectin
- Gilead
- 89bio Inc
- ABIONYX Pharma SA
- Abivax SA
- Abliva AB
- Acquist Therapeutics
- AdAlta Ltd
- Afimmune Biopharma Ltd
- Zhejiang Doer Biologics Corp
- Dicerna Pharmaceuticals Inc
- ChemomAb Ltd
- DURECT Corp
- Eli Lilly and Co
- Enanta Pharmaceuticals Inc
- EncuraGen Inc
- Engitix Ltd
- Heprotech Inc
- Hinova Pharmaceuticals Inc
- HK inno.N Corp
- HotSpot Therapeutics Inc
What is the 10-year outlook for the global NASH Drug Pipeline market?
What factors are driving NASH Drug Pipeline market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do NASH Drug Pipeline market opportunities vary by end market size?
How does NASH Drug Pipeline break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NASH Drug Pipeline Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for NASH Drug Pipeline by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for NASH Drug Pipeline by Country/Region, 2018, 2022 & 2029
2.2 NASH Drug Pipeline Segment by Type
2.2.1 Protease Inhibitor
2.2.2 Immunomodulatory
2.2.3 Multiple Kinase Inhibitor
2.3 NASH Drug Pipeline Sales by Type
2.3.1 Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)
2.3.2 Global NASH Drug Pipeline Revenue and Market Share by Type (2018-2023)
2.3.3 Global NASH Drug Pipeline Sale Price by Type (2018-2023)
2.4 NASH Drug Pipeline Segment by Application
2.4.1 Clinical
2.4.2 Academic Research
2.5 NASH Drug Pipeline Sales by Application
2.5.1 Global NASH Drug Pipeline Sale Market Share by Application (2018-2023)
2.5.2 Global NASH Drug Pipeline Revenue and Market Share by Application (2018-2023)
2.5.3 Global NASH Drug Pipeline Sale Price by Application (2018-2023)
3 GLOBAL NASH DRUG PIPELINE BY COMPANY
3.1 Global NASH Drug Pipeline Breakdown Data by Company
3.1.1 Global NASH Drug Pipeline Annual Sales by Company (2018-2023)
3.1.2 Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)
3.2 Global NASH Drug Pipeline Annual Revenue by Company (2018-2023)
3.2.1 Global NASH Drug Pipeline Revenue by Company (2018-2023)
3.2.2 Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)
3.3 Global NASH Drug Pipeline Sale Price by Company
3.4 Key Manufacturers NASH Drug Pipeline Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NASH Drug Pipeline Product Location Distribution
3.4.2 Players NASH Drug Pipeline Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION
4.1 World Historic NASH Drug Pipeline Market Size by Geographic Region (2018-2023)
4.1.1 Global NASH Drug Pipeline Annual Sales by Geographic Region (2018-2023)
4.1.2 Global NASH Drug Pipeline Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic NASH Drug Pipeline Market Size by Country/Region (2018-2023)
4.2.1 Global NASH Drug Pipeline Annual Sales by Country/Region (2018-2023)
4.2.2 Global NASH Drug Pipeline Annual Revenue by Country/Region (2018-2023)
4.3 Americas NASH Drug Pipeline Sales Growth
4.4 APAC NASH Drug Pipeline Sales Growth
4.5 Europe NASH Drug Pipeline Sales Growth
4.6 Middle East & Africa NASH Drug Pipeline Sales Growth
5 AMERICAS
5.1 Americas NASH Drug Pipeline Sales by Country
5.1.1 Americas NASH Drug Pipeline Sales by Country (2018-2023)
5.1.2 Americas NASH Drug Pipeline Revenue by Country (2018-2023)
5.2 Americas NASH Drug Pipeline Sales by Type
5.3 Americas NASH Drug Pipeline Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NASH Drug Pipeline Sales by Region
6.1.1 APAC NASH Drug Pipeline Sales by Region (2018-2023)
6.1.2 APAC NASH Drug Pipeline Revenue by Region (2018-2023)
6.2 APAC NASH Drug Pipeline Sales by Type
6.3 APAC NASH Drug Pipeline Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NASH Drug Pipeline by Country
7.1.1 Europe NASH Drug Pipeline Sales by Country (2018-2023)
7.1.2 Europe NASH Drug Pipeline Revenue by Country (2018-2023)
7.2 Europe NASH Drug Pipeline Sales by Type
7.3 Europe NASH Drug Pipeline Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NASH Drug Pipeline by Country
8.1.1 Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023)
8.1.2 Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023)
8.2 Middle East & Africa NASH Drug Pipeline Sales by Type
8.3 Middle East & Africa NASH Drug Pipeline Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NASH Drug Pipeline
10.3 Manufacturing Process Analysis of NASH Drug Pipeline
10.4 Industry Chain Structure of NASH Drug Pipeline
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NASH Drug Pipeline Distributors
11.3 NASH Drug Pipeline Customer
12 WORLD FORECAST REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION
12.1 Global NASH Drug Pipeline Market Size Forecast by Region
12.1.1 Global NASH Drug Pipeline Forecast by Region (2024-2029)
12.1.2 Global NASH Drug Pipeline Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global NASH Drug Pipeline Forecast by Type
12.7 Global NASH Drug Pipeline Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Intercept
13.1.1 Intercept Company Information
13.1.2 Intercept NASH Drug Pipeline Product Portfolios and Specifications
13.1.3 Intercept NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Intercept Main Business Overview
13.1.5 Intercept Latest Developments
13.2 Genfit
13.2.1 Genfit Company Information
13.2.2 Genfit NASH Drug Pipeline Product Portfolios and Specifications
13.2.3 Genfit NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Genfit Main Business Overview
13.2.5 Genfit Latest Developments
13.3 Allergan
13.3.1 Allergan Company Information
13.3.2 Allergan NASH Drug Pipeline Product Portfolios and Specifications
13.3.3 Allergan NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Allergan Main Business Overview
13.3.5 Allergan Latest Developments
13.4 Madrigal
13.4.1 Madrigal Company Information
13.4.2 Madrigal NASH Drug Pipeline Product Portfolios and Specifications
13.4.3 Madrigal NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Madrigal Main Business Overview
13.4.5 Madrigal Latest Developments
13.5 Immuron
13.5.1 Immuron Company Information
13.5.2 Immuron NASH Drug Pipeline Product Portfolios and Specifications
13.5.3 Immuron NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Immuron Main Business Overview
13.5.5 Immuron Latest Developments
13.6 Galectin
13.6.1 Galectin Company Information
13.6.2 Galectin NASH Drug Pipeline Product Portfolios and Specifications
13.6.3 Galectin NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Galectin Main Business Overview
13.6.5 Galectin Latest Developments
13.7 Gilead
13.7.1 Gilead Company Information
13.7.2 Gilead NASH Drug Pipeline Product Portfolios and Specifications
13.7.3 Gilead NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Gilead Main Business Overview
13.7.5 Gilead Latest Developments
13.8 89bio Inc
13.8.1 89bio Inc Company Information
13.8.2 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications
13.8.3 89bio Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 89bio Inc Main Business Overview
13.8.5 89bio Inc Latest Developments
13.9 ABIONYX Pharma SA
13.9.1 ABIONYX Pharma SA Company Information
13.9.2 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications
13.9.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 ABIONYX Pharma SA Main Business Overview
13.9.5 ABIONYX Pharma SA Latest Developments
13.10 Abivax SA
13.10.1 Abivax SA Company Information
13.10.2 Abivax SA NASH Drug Pipeline Product Portfolios and Specifications
13.10.3 Abivax SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Abivax SA Main Business Overview
13.10.5 Abivax SA Latest Developments
13.11 Abliva AB
13.11.1 Abliva AB Company Information
13.11.2 Abliva AB NASH Drug Pipeline Product Portfolios and Specifications
13.11.3 Abliva AB NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Abliva AB Main Business Overview
13.11.5 Abliva AB Latest Developments
13.12 Acquist Therapeutics
13.12.1 Acquist Therapeutics Company Information
13.12.2 Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications
13.12.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Acquist Therapeutics Main Business Overview
13.12.5 Acquist Therapeutics Latest Developments
13.13 AdAlta Ltd
13.13.1 AdAlta Ltd Company Information
13.13.2 AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.13.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 AdAlta Ltd Main Business Overview
13.13.5 AdAlta Ltd Latest Developments
13.14 Afimmune Biopharma Ltd
13.14.1 Afimmune Biopharma Ltd Company Information
13.14.2 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.14.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Afimmune Biopharma Ltd Main Business Overview
13.14.5 Afimmune Biopharma Ltd Latest Developments
13.15 Zhejiang Doer Biologics Corp
13.15.1 Zhejiang Doer Biologics Corp Company Information
13.15.2 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications
13.15.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Zhejiang Doer Biologics Corp Main Business Overview
13.15.5 Zhejiang Doer Biologics Corp Latest Developments
13.16 Dicerna Pharmaceuticals Inc
13.16.1 Dicerna Pharmaceuticals Inc Company Information
13.16.2 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.16.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Dicerna Pharmaceuticals Inc Main Business Overview
13.16.5 Dicerna Pharmaceuticals Inc Latest Developments
13.17 ChemomAb Ltd
13.17.1 ChemomAb Ltd Company Information
13.17.2 ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.17.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 ChemomAb Ltd Main Business Overview
13.17.5 ChemomAb Ltd Latest Developments
13.18 DURECT Corp
13.18.1 DURECT Corp Company Information
13.18.2 DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications
13.18.3 DURECT Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 DURECT Corp Main Business Overview
13.18.5 DURECT Corp Latest Developments
13.19 Eli Lilly and Co
13.19.1 Eli Lilly and Co Company Information
13.19.2 Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications
13.19.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Eli Lilly and Co Main Business Overview
13.19.5 Eli Lilly and Co Latest Developments
13.20 Enanta Pharmaceuticals Inc
13.20.1 Enanta Pharmaceuticals Inc Company Information
13.20.2 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.20.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Enanta Pharmaceuticals Inc Main Business Overview
13.20.5 Enanta Pharmaceuticals Inc Latest Developments
13.21 EncuraGen Inc
13.21.1 EncuraGen Inc Company Information
13.21.2 EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications
13.21.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 EncuraGen Inc Main Business Overview
13.21.5 EncuraGen Inc Latest Developments
13.22 Engitix Ltd
13.22.1 Engitix Ltd Company Information
13.22.2 Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.22.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Engitix Ltd Main Business Overview
13.22.5 Engitix Ltd Latest Developments
13.23 Heprotech Inc
13.23.1 Heprotech Inc Company Information
13.23.2 Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications
13.23.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Heprotech Inc Main Business Overview
13.23.5 Heprotech Inc Latest Developments
13.24 Hinova Pharmaceuticals Inc
13.24.1 Hinova Pharmaceuticals Inc Company Information
13.24.2 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.24.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Hinova Pharmaceuticals Inc Main Business Overview
13.24.5 Hinova Pharmaceuticals Inc Latest Developments
13.25 HK inno.N Corp
13.25.1 HK inno.N Corp Company Information
13.25.2 HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications
13.25.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 HK inno.N Corp Main Business Overview
13.25.5 HK inno.N Corp Latest Developments
13.26 HotSpot Therapeutics Inc
13.26.1 HotSpot Therapeutics Inc Company Information
13.26.2 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications
13.26.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 HotSpot Therapeutics Inc Main Business Overview
13.26.5 HotSpot Therapeutics Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global NASH Drug Pipeline Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for NASH Drug Pipeline by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for NASH Drug Pipeline by Country/Region, 2018, 2022 & 2029
2.2 NASH Drug Pipeline Segment by Type
2.2.1 Protease Inhibitor
2.2.2 Immunomodulatory
2.2.3 Multiple Kinase Inhibitor
2.3 NASH Drug Pipeline Sales by Type
2.3.1 Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)
2.3.2 Global NASH Drug Pipeline Revenue and Market Share by Type (2018-2023)
2.3.3 Global NASH Drug Pipeline Sale Price by Type (2018-2023)
2.4 NASH Drug Pipeline Segment by Application
2.4.1 Clinical
2.4.2 Academic Research
2.5 NASH Drug Pipeline Sales by Application
2.5.1 Global NASH Drug Pipeline Sale Market Share by Application (2018-2023)
2.5.2 Global NASH Drug Pipeline Revenue and Market Share by Application (2018-2023)
2.5.3 Global NASH Drug Pipeline Sale Price by Application (2018-2023)
3 GLOBAL NASH DRUG PIPELINE BY COMPANY
3.1 Global NASH Drug Pipeline Breakdown Data by Company
3.1.1 Global NASH Drug Pipeline Annual Sales by Company (2018-2023)
3.1.2 Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)
3.2 Global NASH Drug Pipeline Annual Revenue by Company (2018-2023)
3.2.1 Global NASH Drug Pipeline Revenue by Company (2018-2023)
3.2.2 Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)
3.3 Global NASH Drug Pipeline Sale Price by Company
3.4 Key Manufacturers NASH Drug Pipeline Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers NASH Drug Pipeline Product Location Distribution
3.4.2 Players NASH Drug Pipeline Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION
4.1 World Historic NASH Drug Pipeline Market Size by Geographic Region (2018-2023)
4.1.1 Global NASH Drug Pipeline Annual Sales by Geographic Region (2018-2023)
4.1.2 Global NASH Drug Pipeline Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic NASH Drug Pipeline Market Size by Country/Region (2018-2023)
4.2.1 Global NASH Drug Pipeline Annual Sales by Country/Region (2018-2023)
4.2.2 Global NASH Drug Pipeline Annual Revenue by Country/Region (2018-2023)
4.3 Americas NASH Drug Pipeline Sales Growth
4.4 APAC NASH Drug Pipeline Sales Growth
4.5 Europe NASH Drug Pipeline Sales Growth
4.6 Middle East & Africa NASH Drug Pipeline Sales Growth
5 AMERICAS
5.1 Americas NASH Drug Pipeline Sales by Country
5.1.1 Americas NASH Drug Pipeline Sales by Country (2018-2023)
5.1.2 Americas NASH Drug Pipeline Revenue by Country (2018-2023)
5.2 Americas NASH Drug Pipeline Sales by Type
5.3 Americas NASH Drug Pipeline Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC NASH Drug Pipeline Sales by Region
6.1.1 APAC NASH Drug Pipeline Sales by Region (2018-2023)
6.1.2 APAC NASH Drug Pipeline Revenue by Region (2018-2023)
6.2 APAC NASH Drug Pipeline Sales by Type
6.3 APAC NASH Drug Pipeline Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe NASH Drug Pipeline by Country
7.1.1 Europe NASH Drug Pipeline Sales by Country (2018-2023)
7.1.2 Europe NASH Drug Pipeline Revenue by Country (2018-2023)
7.2 Europe NASH Drug Pipeline Sales by Type
7.3 Europe NASH Drug Pipeline Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa NASH Drug Pipeline by Country
8.1.1 Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023)
8.1.2 Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023)
8.2 Middle East & Africa NASH Drug Pipeline Sales by Type
8.3 Middle East & Africa NASH Drug Pipeline Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of NASH Drug Pipeline
10.3 Manufacturing Process Analysis of NASH Drug Pipeline
10.4 Industry Chain Structure of NASH Drug Pipeline
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 NASH Drug Pipeline Distributors
11.3 NASH Drug Pipeline Customer
12 WORLD FORECAST REVIEW FOR NASH DRUG PIPELINE BY GEOGRAPHIC REGION
12.1 Global NASH Drug Pipeline Market Size Forecast by Region
12.1.1 Global NASH Drug Pipeline Forecast by Region (2024-2029)
12.1.2 Global NASH Drug Pipeline Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global NASH Drug Pipeline Forecast by Type
12.7 Global NASH Drug Pipeline Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Intercept
13.1.1 Intercept Company Information
13.1.2 Intercept NASH Drug Pipeline Product Portfolios and Specifications
13.1.3 Intercept NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Intercept Main Business Overview
13.1.5 Intercept Latest Developments
13.2 Genfit
13.2.1 Genfit Company Information
13.2.2 Genfit NASH Drug Pipeline Product Portfolios and Specifications
13.2.3 Genfit NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Genfit Main Business Overview
13.2.5 Genfit Latest Developments
13.3 Allergan
13.3.1 Allergan Company Information
13.3.2 Allergan NASH Drug Pipeline Product Portfolios and Specifications
13.3.3 Allergan NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Allergan Main Business Overview
13.3.5 Allergan Latest Developments
13.4 Madrigal
13.4.1 Madrigal Company Information
13.4.2 Madrigal NASH Drug Pipeline Product Portfolios and Specifications
13.4.3 Madrigal NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Madrigal Main Business Overview
13.4.5 Madrigal Latest Developments
13.5 Immuron
13.5.1 Immuron Company Information
13.5.2 Immuron NASH Drug Pipeline Product Portfolios and Specifications
13.5.3 Immuron NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Immuron Main Business Overview
13.5.5 Immuron Latest Developments
13.6 Galectin
13.6.1 Galectin Company Information
13.6.2 Galectin NASH Drug Pipeline Product Portfolios and Specifications
13.6.3 Galectin NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Galectin Main Business Overview
13.6.5 Galectin Latest Developments
13.7 Gilead
13.7.1 Gilead Company Information
13.7.2 Gilead NASH Drug Pipeline Product Portfolios and Specifications
13.7.3 Gilead NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Gilead Main Business Overview
13.7.5 Gilead Latest Developments
13.8 89bio Inc
13.8.1 89bio Inc Company Information
13.8.2 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications
13.8.3 89bio Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 89bio Inc Main Business Overview
13.8.5 89bio Inc Latest Developments
13.9 ABIONYX Pharma SA
13.9.1 ABIONYX Pharma SA Company Information
13.9.2 ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications
13.9.3 ABIONYX Pharma SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 ABIONYX Pharma SA Main Business Overview
13.9.5 ABIONYX Pharma SA Latest Developments
13.10 Abivax SA
13.10.1 Abivax SA Company Information
13.10.2 Abivax SA NASH Drug Pipeline Product Portfolios and Specifications
13.10.3 Abivax SA NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Abivax SA Main Business Overview
13.10.5 Abivax SA Latest Developments
13.11 Abliva AB
13.11.1 Abliva AB Company Information
13.11.2 Abliva AB NASH Drug Pipeline Product Portfolios and Specifications
13.11.3 Abliva AB NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Abliva AB Main Business Overview
13.11.5 Abliva AB Latest Developments
13.12 Acquist Therapeutics
13.12.1 Acquist Therapeutics Company Information
13.12.2 Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications
13.12.3 Acquist Therapeutics NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Acquist Therapeutics Main Business Overview
13.12.5 Acquist Therapeutics Latest Developments
13.13 AdAlta Ltd
13.13.1 AdAlta Ltd Company Information
13.13.2 AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.13.3 AdAlta Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 AdAlta Ltd Main Business Overview
13.13.5 AdAlta Ltd Latest Developments
13.14 Afimmune Biopharma Ltd
13.14.1 Afimmune Biopharma Ltd Company Information
13.14.2 Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.14.3 Afimmune Biopharma Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Afimmune Biopharma Ltd Main Business Overview
13.14.5 Afimmune Biopharma Ltd Latest Developments
13.15 Zhejiang Doer Biologics Corp
13.15.1 Zhejiang Doer Biologics Corp Company Information
13.15.2 Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications
13.15.3 Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Zhejiang Doer Biologics Corp Main Business Overview
13.15.5 Zhejiang Doer Biologics Corp Latest Developments
13.16 Dicerna Pharmaceuticals Inc
13.16.1 Dicerna Pharmaceuticals Inc Company Information
13.16.2 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.16.3 Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.16.4 Dicerna Pharmaceuticals Inc Main Business Overview
13.16.5 Dicerna Pharmaceuticals Inc Latest Developments
13.17 ChemomAb Ltd
13.17.1 ChemomAb Ltd Company Information
13.17.2 ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.17.3 ChemomAb Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.17.4 ChemomAb Ltd Main Business Overview
13.17.5 ChemomAb Ltd Latest Developments
13.18 DURECT Corp
13.18.1 DURECT Corp Company Information
13.18.2 DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications
13.18.3 DURECT Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.18.4 DURECT Corp Main Business Overview
13.18.5 DURECT Corp Latest Developments
13.19 Eli Lilly and Co
13.19.1 Eli Lilly and Co Company Information
13.19.2 Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications
13.19.3 Eli Lilly and Co NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.19.4 Eli Lilly and Co Main Business Overview
13.19.5 Eli Lilly and Co Latest Developments
13.20 Enanta Pharmaceuticals Inc
13.20.1 Enanta Pharmaceuticals Inc Company Information
13.20.2 Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.20.3 Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.20.4 Enanta Pharmaceuticals Inc Main Business Overview
13.20.5 Enanta Pharmaceuticals Inc Latest Developments
13.21 EncuraGen Inc
13.21.1 EncuraGen Inc Company Information
13.21.2 EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications
13.21.3 EncuraGen Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.21.4 EncuraGen Inc Main Business Overview
13.21.5 EncuraGen Inc Latest Developments
13.22 Engitix Ltd
13.22.1 Engitix Ltd Company Information
13.22.2 Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications
13.22.3 Engitix Ltd NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.22.4 Engitix Ltd Main Business Overview
13.22.5 Engitix Ltd Latest Developments
13.23 Heprotech Inc
13.23.1 Heprotech Inc Company Information
13.23.2 Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications
13.23.3 Heprotech Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.23.4 Heprotech Inc Main Business Overview
13.23.5 Heprotech Inc Latest Developments
13.24 Hinova Pharmaceuticals Inc
13.24.1 Hinova Pharmaceuticals Inc Company Information
13.24.2 Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
13.24.3 Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.24.4 Hinova Pharmaceuticals Inc Main Business Overview
13.24.5 Hinova Pharmaceuticals Inc Latest Developments
13.25 HK inno.N Corp
13.25.1 HK inno.N Corp Company Information
13.25.2 HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications
13.25.3 HK inno.N Corp NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.25.4 HK inno.N Corp Main Business Overview
13.25.5 HK inno.N Corp Latest Developments
13.26 HotSpot Therapeutics Inc
13.26.1 HotSpot Therapeutics Inc Company Information
13.26.2 HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications
13.26.3 HotSpot Therapeutics Inc NASH Drug Pipeline Sales, Revenue, Price and Gross Margin (2018-2023)
13.26.4 HotSpot Therapeutics Inc Main Business Overview
13.26.5 HotSpot Therapeutics Inc Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. NASH Drug Pipeline Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. NASH Drug Pipeline Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Protease Inhibitor
Table 4. Major Players of Immunomodulatory
Table 5. Major Players of Multiple Kinase Inhibitor
Table 6. Global NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 7. Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Table 8. Global NASH Drug Pipeline Revenue by Type (2018-2023) & ($ million)
Table 9. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)
Table 10. Global NASH Drug Pipeline Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 12. Global NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Table 13. Global NASH Drug Pipeline Revenue by Application (2018-2023)
Table 14. Global NASH Drug Pipeline Revenue Market Share by Application (2018-2023)
Table 15. Global NASH Drug Pipeline Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global NASH Drug Pipeline Sales by Company (2018-2023) & (K Units)
Table 17. Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)
Table 18. Global NASH Drug Pipeline Revenue by Company (2018-2023) ($ Millions)
Table 19. Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)
Table 20. Global NASH Drug Pipeline Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers NASH Drug Pipeline Producing Area Distribution and Sales Area
Table 22. Players NASH Drug Pipeline Products Offered
Table 23. NASH Drug Pipeline Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global NASH Drug Pipeline Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global NASH Drug Pipeline Sales Market Share Geographic Region (2018-2023)
Table 28. Global NASH Drug Pipeline Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global NASH Drug Pipeline Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global NASH Drug Pipeline Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global NASH Drug Pipeline Sales Market Share by Country/Region (2018-2023)
Table 32. Global NASH Drug Pipeline Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global NASH Drug Pipeline Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 35. Americas NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 36. Americas NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 38. Americas NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 39. Americas NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 40. APAC NASH Drug Pipeline Sales by Region (2018-2023) & (K Units)
Table 41. APAC NASH Drug Pipeline Sales Market Share by Region (2018-2023)
Table 42. APAC NASH Drug Pipeline Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC NASH Drug Pipeline Revenue Market Share by Region (2018-2023)
Table 44. APAC NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 45. APAC NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 46. Europe NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 47. Europe NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 48. Europe NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 50. Europe NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 51. Europe NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of NASH Drug Pipeline
Table 59. Key Market Challenges & Risks of NASH Drug Pipeline
Table 60. Key Industry Trends of NASH Drug Pipeline
Table 61. NASH Drug Pipeline Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. NASH Drug Pipeline Distributors List
Table 64. NASH Drug Pipeline Customer List
Table 65. Global NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global NASH Drug Pipeline Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global NASH Drug Pipeline Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global NASH Drug Pipeline Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global NASH Drug Pipeline Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Intercept Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 80. Intercept NASH Drug Pipeline Product Portfolios and Specifications
Table 81. Intercept NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Intercept Main Business
Table 83. Intercept Latest Developments
Table 84. Genfit Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 85. Genfit NASH Drug Pipeline Product Portfolios and Specifications
Table 86. Genfit NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Genfit Main Business
Table 88. Genfit Latest Developments
Table 89. Allergan Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 90. Allergan NASH Drug Pipeline Product Portfolios and Specifications
Table 91. Allergan NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Allergan Main Business
Table 93. Allergan Latest Developments
Table 94. Madrigal Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 95. Madrigal NASH Drug Pipeline Product Portfolios and Specifications
Table 96. Madrigal NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Madrigal Main Business
Table 98. Madrigal Latest Developments
Table 99. Immuron Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 100. Immuron NASH Drug Pipeline Product Portfolios and Specifications
Table 101. Immuron NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Immuron Main Business
Table 103. Immuron Latest Developments
Table 104. Galectin Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 105. Galectin NASH Drug Pipeline Product Portfolios and Specifications
Table 106. Galectin NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Galectin Main Business
Table 108. Galectin Latest Developments
Table 109. Gilead Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 110. Gilead NASH Drug Pipeline Product Portfolios and Specifications
Table 111. Gilead NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Gilead Main Business
Table 113. Gilead Latest Developments
Table 114. 89bio Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 115. 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 116. 89bio Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. 89bio Inc Main Business
Table 118. 89bio Inc Latest Developments
Table 119. ABIONYX Pharma SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 120. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications
Table 121. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. ABIONYX Pharma SA Main Business
Table 123. ABIONYX Pharma SA Latest Developments
Table 124. Abivax SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 125. Abivax SA NASH Drug Pipeline Product Portfolios and Specifications
Table 126. Abivax SA NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Abivax SA Main Business
Table 128. Abivax SA Latest Developments
Table 129. Abliva AB Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 130. Abliva AB NASH Drug Pipeline Product Portfolios and Specifications
Table 131. Abliva AB NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Abliva AB Main Business
Table 133. Abliva AB Latest Developments
Table 134. Acquist Therapeutics Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 135. Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications
Table 136. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Acquist Therapeutics Main Business
Table 138. Acquist Therapeutics Latest Developments
Table 139. AdAlta Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 140. AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 141. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. AdAlta Ltd Main Business
Table 143. AdAlta Ltd Latest Developments
Table 144. Afimmune Biopharma Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 145. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 146. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Afimmune Biopharma Ltd Main Business
Table 148. Afimmune Biopharma Ltd Latest Developments
Table 149. Zhejiang Doer Biologics Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 150. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 151. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Zhejiang Doer Biologics Corp Main Business
Table 153. Zhejiang Doer Biologics Corp Latest Developments
Table 154. Dicerna Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 155. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 156. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. Dicerna Pharmaceuticals Inc Main Business
Table 158. Dicerna Pharmaceuticals Inc Latest Developments
Table 159. ChemomAb Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 160. ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 161. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. ChemomAb Ltd Main Business
Table 163. ChemomAb Ltd Latest Developments
Table 164. DURECT Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 165. DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 166. DURECT Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 167. DURECT Corp Main Business
Table 168. DURECT Corp Latest Developments
Table 169. Eli Lilly and Co Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 170. Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications
Table 171. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 172. Eli Lilly and Co Main Business
Table 173. Eli Lilly and Co Latest Developments
Table 174. Enanta Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 175. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 176. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 177. Enanta Pharmaceuticals Inc Main Business
Table 178. Enanta Pharmaceuticals Inc Latest Developments
Table 179. EncuraGen Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 180. EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 181. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 182. EncuraGen Inc Main Business
Table 183. EncuraGen Inc Latest Developments
Table 184. Engitix Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 185. Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 186. Engitix Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 187. Engitix Ltd Main Business
Table 188. Engitix Ltd Latest Developments
Table 189. Heprotech Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 190. Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 191. Heprotech Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 192. Heprotech Inc Main Business
Table 193. Heprotech Inc Latest Developments
Table 194. Hinova Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 195. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 196. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 197. Hinova Pharmaceuticals Inc Main Business
Table 198. Hinova Pharmaceuticals Inc Latest Developments
Table 199. HK inno.N Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 200. HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 201. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 202. HK inno.N Corp Main Business
Table 203. HK inno.N Corp Latest Developments
Table 204. HotSpot Therapeutics Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 205. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 206. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 207. HotSpot Therapeutics Inc Main Business
Table 208. HotSpot Therapeutics Inc Latest Developments
Table 1. NASH Drug Pipeline Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. NASH Drug Pipeline Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Protease Inhibitor
Table 4. Major Players of Immunomodulatory
Table 5. Major Players of Multiple Kinase Inhibitor
Table 6. Global NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 7. Global NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Table 8. Global NASH Drug Pipeline Revenue by Type (2018-2023) & ($ million)
Table 9. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)
Table 10. Global NASH Drug Pipeline Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 12. Global NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Table 13. Global NASH Drug Pipeline Revenue by Application (2018-2023)
Table 14. Global NASH Drug Pipeline Revenue Market Share by Application (2018-2023)
Table 15. Global NASH Drug Pipeline Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global NASH Drug Pipeline Sales by Company (2018-2023) & (K Units)
Table 17. Global NASH Drug Pipeline Sales Market Share by Company (2018-2023)
Table 18. Global NASH Drug Pipeline Revenue by Company (2018-2023) ($ Millions)
Table 19. Global NASH Drug Pipeline Revenue Market Share by Company (2018-2023)
Table 20. Global NASH Drug Pipeline Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers NASH Drug Pipeline Producing Area Distribution and Sales Area
Table 22. Players NASH Drug Pipeline Products Offered
Table 23. NASH Drug Pipeline Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global NASH Drug Pipeline Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global NASH Drug Pipeline Sales Market Share Geographic Region (2018-2023)
Table 28. Global NASH Drug Pipeline Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global NASH Drug Pipeline Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global NASH Drug Pipeline Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global NASH Drug Pipeline Sales Market Share by Country/Region (2018-2023)
Table 32. Global NASH Drug Pipeline Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global NASH Drug Pipeline Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 35. Americas NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 36. Americas NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 38. Americas NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 39. Americas NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 40. APAC NASH Drug Pipeline Sales by Region (2018-2023) & (K Units)
Table 41. APAC NASH Drug Pipeline Sales Market Share by Region (2018-2023)
Table 42. APAC NASH Drug Pipeline Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC NASH Drug Pipeline Revenue Market Share by Region (2018-2023)
Table 44. APAC NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 45. APAC NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 46. Europe NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 47. Europe NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 48. Europe NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 50. Europe NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 51. Europe NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa NASH Drug Pipeline Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa NASH Drug Pipeline Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa NASH Drug Pipeline Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa NASH Drug Pipeline Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of NASH Drug Pipeline
Table 59. Key Market Challenges & Risks of NASH Drug Pipeline
Table 60. Key Industry Trends of NASH Drug Pipeline
Table 61. NASH Drug Pipeline Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. NASH Drug Pipeline Distributors List
Table 64. NASH Drug Pipeline Customer List
Table 65. Global NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC NASH Drug Pipeline Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC NASH Drug Pipeline Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa NASH Drug Pipeline Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa NASH Drug Pipeline Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global NASH Drug Pipeline Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global NASH Drug Pipeline Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global NASH Drug Pipeline Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global NASH Drug Pipeline Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Intercept Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 80. Intercept NASH Drug Pipeline Product Portfolios and Specifications
Table 81. Intercept NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Intercept Main Business
Table 83. Intercept Latest Developments
Table 84. Genfit Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 85. Genfit NASH Drug Pipeline Product Portfolios and Specifications
Table 86. Genfit NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Genfit Main Business
Table 88. Genfit Latest Developments
Table 89. Allergan Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 90. Allergan NASH Drug Pipeline Product Portfolios and Specifications
Table 91. Allergan NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Allergan Main Business
Table 93. Allergan Latest Developments
Table 94. Madrigal Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 95. Madrigal NASH Drug Pipeline Product Portfolios and Specifications
Table 96. Madrigal NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Madrigal Main Business
Table 98. Madrigal Latest Developments
Table 99. Immuron Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 100. Immuron NASH Drug Pipeline Product Portfolios and Specifications
Table 101. Immuron NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Immuron Main Business
Table 103. Immuron Latest Developments
Table 104. Galectin Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 105. Galectin NASH Drug Pipeline Product Portfolios and Specifications
Table 106. Galectin NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Galectin Main Business
Table 108. Galectin Latest Developments
Table 109. Gilead Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 110. Gilead NASH Drug Pipeline Product Portfolios and Specifications
Table 111. Gilead NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Gilead Main Business
Table 113. Gilead Latest Developments
Table 114. 89bio Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 115. 89bio Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 116. 89bio Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. 89bio Inc Main Business
Table 118. 89bio Inc Latest Developments
Table 119. ABIONYX Pharma SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 120. ABIONYX Pharma SA NASH Drug Pipeline Product Portfolios and Specifications
Table 121. ABIONYX Pharma SA NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. ABIONYX Pharma SA Main Business
Table 123. ABIONYX Pharma SA Latest Developments
Table 124. Abivax SA Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 125. Abivax SA NASH Drug Pipeline Product Portfolios and Specifications
Table 126. Abivax SA NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Abivax SA Main Business
Table 128. Abivax SA Latest Developments
Table 129. Abliva AB Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 130. Abliva AB NASH Drug Pipeline Product Portfolios and Specifications
Table 131. Abliva AB NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. Abliva AB Main Business
Table 133. Abliva AB Latest Developments
Table 134. Acquist Therapeutics Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 135. Acquist Therapeutics NASH Drug Pipeline Product Portfolios and Specifications
Table 136. Acquist Therapeutics NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Acquist Therapeutics Main Business
Table 138. Acquist Therapeutics Latest Developments
Table 139. AdAlta Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 140. AdAlta Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 141. AdAlta Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. AdAlta Ltd Main Business
Table 143. AdAlta Ltd Latest Developments
Table 144. Afimmune Biopharma Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 145. Afimmune Biopharma Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 146. Afimmune Biopharma Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Afimmune Biopharma Ltd Main Business
Table 148. Afimmune Biopharma Ltd Latest Developments
Table 149. Zhejiang Doer Biologics Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 150. Zhejiang Doer Biologics Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 151. Zhejiang Doer Biologics Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Zhejiang Doer Biologics Corp Main Business
Table 153. Zhejiang Doer Biologics Corp Latest Developments
Table 154. Dicerna Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 155. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 156. Dicerna Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 157. Dicerna Pharmaceuticals Inc Main Business
Table 158. Dicerna Pharmaceuticals Inc Latest Developments
Table 159. ChemomAb Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 160. ChemomAb Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 161. ChemomAb Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 162. ChemomAb Ltd Main Business
Table 163. ChemomAb Ltd Latest Developments
Table 164. DURECT Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 165. DURECT Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 166. DURECT Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 167. DURECT Corp Main Business
Table 168. DURECT Corp Latest Developments
Table 169. Eli Lilly and Co Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 170. Eli Lilly and Co NASH Drug Pipeline Product Portfolios and Specifications
Table 171. Eli Lilly and Co NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 172. Eli Lilly and Co Main Business
Table 173. Eli Lilly and Co Latest Developments
Table 174. Enanta Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 175. Enanta Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 176. Enanta Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 177. Enanta Pharmaceuticals Inc Main Business
Table 178. Enanta Pharmaceuticals Inc Latest Developments
Table 179. EncuraGen Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 180. EncuraGen Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 181. EncuraGen Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 182. EncuraGen Inc Main Business
Table 183. EncuraGen Inc Latest Developments
Table 184. Engitix Ltd Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 185. Engitix Ltd NASH Drug Pipeline Product Portfolios and Specifications
Table 186. Engitix Ltd NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 187. Engitix Ltd Main Business
Table 188. Engitix Ltd Latest Developments
Table 189. Heprotech Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 190. Heprotech Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 191. Heprotech Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 192. Heprotech Inc Main Business
Table 193. Heprotech Inc Latest Developments
Table 194. Hinova Pharmaceuticals Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 195. Hinova Pharmaceuticals Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 196. Hinova Pharmaceuticals Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 197. Hinova Pharmaceuticals Inc Main Business
Table 198. Hinova Pharmaceuticals Inc Latest Developments
Table 199. HK inno.N Corp Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 200. HK inno.N Corp NASH Drug Pipeline Product Portfolios and Specifications
Table 201. HK inno.N Corp NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 202. HK inno.N Corp Main Business
Table 203. HK inno.N Corp Latest Developments
Table 204. HotSpot Therapeutics Inc Basic Information, NASH Drug Pipeline Manufacturing Base, Sales Area and Its Competitors
Table 205. HotSpot Therapeutics Inc NASH Drug Pipeline Product Portfolios and Specifications
Table 206. HotSpot Therapeutics Inc NASH Drug Pipeline Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 207. HotSpot Therapeutics Inc Main Business
Table 208. HotSpot Therapeutics Inc Latest Developments
LIST OF FIGURES
Figure 1. Picture of NASH Drug Pipeline
Figure 2. NASH Drug Pipeline Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NASH Drug Pipeline Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global NASH Drug Pipeline Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. NASH Drug Pipeline Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Protease Inhibitor
Figure 10. Product Picture of Immunomodulatory
Figure 11. Product Picture of Multiple Kinase Inhibitor
Figure 12. Global NASH Drug Pipeline Sales Market Share by Type in 2022
Figure 13. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)
Figure 14. NASH Drug Pipeline Consumed in Clinical
Figure 15. Global NASH Drug Pipeline Market: Clinical (2018-2023) & (K Units)
Figure 16. NASH Drug Pipeline Consumed in Academic Research
Figure 17. Global NASH Drug Pipeline Market: Academic Research (2018-2023) & (K Units)
Figure 18. Global NASH Drug Pipeline Sales Market Share by Application (2022)
Figure 19. Global NASH Drug Pipeline Revenue Market Share by Application in 2022
Figure 20. NASH Drug Pipeline Sales Market by Company in 2022 (K Units)
Figure 21. Global NASH Drug Pipeline Sales Market Share by Company in 2022
Figure 22. NASH Drug Pipeline Revenue Market by Company in 2022 ($ Million)
Figure 23. Global NASH Drug Pipeline Revenue Market Share by Company in 2022
Figure 24. Global NASH Drug Pipeline Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global NASH Drug Pipeline Revenue Market Share by Geographic Region in 2022
Figure 26. Americas NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 27. Americas NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 28. APAC NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 29. APAC NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 30. Europe NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 31. Europe NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 34. Americas NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 35. Americas NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 36. Americas NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 37. Americas NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 38. United States NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC NASH Drug Pipeline Sales Market Share by Region in 2022
Figure 43. APAC NASH Drug Pipeline Revenue Market Share by Regions in 2022
Figure 44. APAC NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 45. APAC NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 46. China NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 50. India NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 54. Europe NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 55. Europe NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 56. Europe NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 57. Germany NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 58. France NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 63. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 66. Egypt NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of NASH Drug Pipeline in 2022
Figure 72. Manufacturing Process Analysis of NASH Drug Pipeline
Figure 73. Industry Chain Structure of NASH Drug Pipeline
Figure 74. Channels of Distribution
Figure 75. Global NASH Drug Pipeline Sales Market Forecast by Region (2024-2029)
Figure 76. Global NASH Drug Pipeline Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global NASH Drug Pipeline Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global NASH Drug Pipeline Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global NASH Drug Pipeline Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global NASH Drug Pipeline Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of NASH Drug Pipeline
Figure 2. NASH Drug Pipeline Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global NASH Drug Pipeline Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global NASH Drug Pipeline Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. NASH Drug Pipeline Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Protease Inhibitor
Figure 10. Product Picture of Immunomodulatory
Figure 11. Product Picture of Multiple Kinase Inhibitor
Figure 12. Global NASH Drug Pipeline Sales Market Share by Type in 2022
Figure 13. Global NASH Drug Pipeline Revenue Market Share by Type (2018-2023)
Figure 14. NASH Drug Pipeline Consumed in Clinical
Figure 15. Global NASH Drug Pipeline Market: Clinical (2018-2023) & (K Units)
Figure 16. NASH Drug Pipeline Consumed in Academic Research
Figure 17. Global NASH Drug Pipeline Market: Academic Research (2018-2023) & (K Units)
Figure 18. Global NASH Drug Pipeline Sales Market Share by Application (2022)
Figure 19. Global NASH Drug Pipeline Revenue Market Share by Application in 2022
Figure 20. NASH Drug Pipeline Sales Market by Company in 2022 (K Units)
Figure 21. Global NASH Drug Pipeline Sales Market Share by Company in 2022
Figure 22. NASH Drug Pipeline Revenue Market by Company in 2022 ($ Million)
Figure 23. Global NASH Drug Pipeline Revenue Market Share by Company in 2022
Figure 24. Global NASH Drug Pipeline Sales Market Share by Geographic Region (2018-2023)
Figure 25. Global NASH Drug Pipeline Revenue Market Share by Geographic Region in 2022
Figure 26. Americas NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 27. Americas NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 28. APAC NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 29. APAC NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 30. Europe NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 31. Europe NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 32. Middle East & Africa NASH Drug Pipeline Sales 2018-2023 (K Units)
Figure 33. Middle East & Africa NASH Drug Pipeline Revenue 2018-2023 ($ Millions)
Figure 34. Americas NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 35. Americas NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 36. Americas NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 37. Americas NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 38. United States NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 39. Canada NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 40. Mexico NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 41. Brazil NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 42. APAC NASH Drug Pipeline Sales Market Share by Region in 2022
Figure 43. APAC NASH Drug Pipeline Revenue Market Share by Regions in 2022
Figure 44. APAC NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 45. APAC NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 46. China NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 47. Japan NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 48. South Korea NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 49. Southeast Asia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 50. India NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 51. Australia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 52. China Taiwan NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 53. Europe NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 54. Europe NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 55. Europe NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 56. Europe NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 57. Germany NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 58. France NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 59. UK NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 60. Italy NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 61. Russia NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 62. Middle East & Africa NASH Drug Pipeline Sales Market Share by Country in 2022
Figure 63. Middle East & Africa NASH Drug Pipeline Revenue Market Share by Country in 2022
Figure 64. Middle East & Africa NASH Drug Pipeline Sales Market Share by Type (2018-2023)
Figure 65. Middle East & Africa NASH Drug Pipeline Sales Market Share by Application (2018-2023)
Figure 66. Egypt NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 67. South Africa NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 68. Israel NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 69. Turkey NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 70. GCC Country NASH Drug Pipeline Revenue Growth 2018-2023 ($ Millions)
Figure 71. Manufacturing Cost Structure Analysis of NASH Drug Pipeline in 2022
Figure 72. Manufacturing Process Analysis of NASH Drug Pipeline
Figure 73. Industry Chain Structure of NASH Drug Pipeline
Figure 74. Channels of Distribution
Figure 75. Global NASH Drug Pipeline Sales Market Forecast by Region (2024-2029)
Figure 76. Global NASH Drug Pipeline Revenue Market Share Forecast by Region (2024-2029)
Figure 77. Global NASH Drug Pipeline Sales Market Share Forecast by Type (2024-2029)
Figure 78. Global NASH Drug Pipeline Revenue Market Share Forecast by Type (2024-2029)
Figure 79. Global NASH Drug Pipeline Sales Market Share Forecast by Application (2024-2029)
Figure 80. Global NASH Drug Pipeline Revenue Market Share Forecast by Application (2024-2029)
